3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Curative Biotechnology's 3-Year ROIIC % for the quarter that ended in Dec. 2022 was 0.00%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Curative Biotechnology's 3-Year ROIIC % or its related term are showing as below:
CUBT's 3-Year ROIIC % is not ranked *
in the Biotechnology industry.
Industry Median: -4.63 * Ranked among companies with meaningful 3-Year ROIIC % only.
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Curative Biotechnology 3-Year ROIIC % Related Terms
Curative Biotechnology 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Curative Biotechnology's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CUBT vs ORGS, SNSE, TNXP: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, Curative Biotechnology's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Curative Biotechnology 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Curative Biotechnology's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Curative Biotechnology's 3-Year ROIIC % falls into.
Curative Biotechnology's 3-Year ROIIC % for the quarter that ended in Dec. 2022 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -4.436 (Dec. 2022) - -0.005 (Dec. 2019) )
/
( 3.112 (Dec. 2022) - 0.04 (Dec. 2019) )
=
-4.431
/
3.072
=
-144.24%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Curative Biotechnology (CUBT) has a 3-Year ROIIC % of 0.00 as of Dec. 2022. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Curative Biotechnology and its competitors.
Is Curative Biotechnology's 3-Year ROIIC % too high?
Curative Biotechnology's current 3-Year ROIIC % is 0.00.
How does Curative Biotechnology's 3-Year ROIIC % compare to ORGS and SNSE?
Curative Biotechnology's 3-Year ROIIC % of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Curative Biotechnology and its competitors. Curative Biotechnology's current 3-Year ROIIC % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Curative Biotechnology stock overvalued right now?
Curative Biotechnology (CUBT) has a current 3-Year ROIIC % of 0.00. The current 3-Year ROIIC % is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Curative Biotechnology (CUBT), the current 3-Year ROIIC % is 0.00 as of Dec. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Curative Biotechnology Inc is a development-stage biomedical company focusing on novel treatments for rare diseases. The Company is identifying, acquiring, and developing disease-modifying therapeutic drug candidates with a concentration on rare disease indications. Curative Biotech currently has ongoing programs in three different therapeutic areas: degenerative eye disease, infectious disease, and neuro-oncology. The Company is now concentrating its energy and resources on its degenerative eye disease platform.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CUBT has been successfully added to your 